Rephonic
Artwork for Decera Clinical Education Oncology Podcast

Decera Clinical Education Oncology Podcast

Decera Clinical Education
Non-Small Cell Lung Cancer
BTK Inhibitors
Multiple Myeloma
Chronic Lymphocytic Leukemia
CAR T-Cell Therapy
Bispecific Antibodies
Clinical Trials
Biomarker Testing
Breast Cancer
CDK4/6 Inhibitors
Ovarian Cancer
Immunotherapy
Her2-Positive Metastatic Breast Cancer
ROS1
Polycythemia Vera
Essential Thrombocythemia
Mantle Cell Lymphoma
Venetoclax
Endometrial Cancer
NCCN Guidelines

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

PublishesWeeklyEpisodes274Founded6 years ago
Number of ListenersCategories
CoursesEducationHealth & FitnessMedicine

Listen to this Podcast

Artwork for Decera Clinical Education Oncology Podcast

Latest Episodes

In this podcast episode, Christine M. Bestvina, MD, and Joshua E. Reuss, MD, discuss the current and emerging role of TROP2-directed ADCs in NSCLC, including:

• Current clinical use of Dato-DXd in previously treated EGFR-mutated NSCLC, including evi... more

YouTube

In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss evolving therapy in newly diagnosed multiple myeloma, including:

• Selecting quadruplet therapy

• Optimal use of bortezomib

• The role of autologous stem cell transplantation... more

YouTube

In this podcast episode, Neeraj Agarwal, MD, FASCO, and Emmanuel S. Antonarakis, MD, discuss the evolving role of PARP inhibitors in metastatic prostate cancer, emphasizing early molecular testing to identify appropriate patients for PARP-directed th... more

YouTube

Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.... more

YouTube

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Two Onc Docs
Two Onc DocsSam and Karine
Plenary Session
Plenary SessionVinay Prasad, MD MPH
NEJM This Week
NEJM This WeekNEJM Group

Recent Guests

Michael Sprintz
Clinician discussing multimodal acute pain management and opioid-sparing care
Episode: TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies
Mitchell Engel
Clinician discussing voltage-gated sodium channels and acute pain treatment
Episode: TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies
Amanda Zimmerman
Clinician discussing practical approaches to acute pain
Episode: TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies
Kathy Cates
Clinician presenting acute pain cases and treatment considerations
Episode: TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies
Jesus G. Berdeja
Director of Myeloma Research at Greco-Hainsworth Centers for Research and partner at Tennessee Oncology
Tennessee Oncology
Episode: Experts Discuss Key Topics in Treatment for Newly Diagnosed Multiple Myeloma
Ajai Chari
Professor of Clinical Medicine and Director of the Multiple Myeloma Program at UCSF
UCSF Helen Diller Family Comprehensive Cancer Center
Episode: Experts Discuss Key Topics in Treatment for Newly Diagnosed Multiple Myeloma
Neeraj Agarwal
GU Medical Oncologist, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Episode: PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management
Emmanuel Antonarakis
Prostate cancer expert and authority in the field
Episode: PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management
Hope Rugo
Dr. Hope Rugo is a physician at City of Hope Comprehensive Cancer Center
City of Hope Comprehensive Cancer Center
Episode: ASCO 2026 Updates in Metastatic Breast Cancer

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts
#151
Australia/Education/Courses
Apple Podcasts
#79
Saudi Arabia/Education/Courses
Apple Podcasts
#84
Sweden/Education/Courses
Apple Podcasts
#99
Japan/Education/Courses
Apple Podcasts
#118
Netherlands/Education/Courses
Apple Podcasts
#141
Brazil/Education/Courses
Apple Podcasts
#177
India/Education/Courses
Apple Podcasts
#192
Argentina/Education/Courses

Talking Points

Recent interactions between the hosts and their guests.

Experts Discuss Sequencing of Therapies for Relapsed/Refractory Multiple Myeloma
Q: If you are deciding between CAR-Ts and bispecifics or ADCs, how are you picking?
They consider CAR T eligibility, disease pace, patient preference, infection risk, treatment logistics, and access. They generally favor discussing CAR T first when appropriate, while bispecifics or ADCs may suit patients who are ineligible or face particular risks or access barriers.
Experts Discuss Sequencing of Therapies for Relapsed/Refractory Multiple Myeloma
Q: In a patient who is relapsing after one or two prior lines of therapy, what are our options now?
The speakers review evidence for CAR T-cell therapies, antibody-drug conjugate combinations, and bispecific antibodies, noting that studies have compared these approaches with standard triplet regimens and reported strong outcomes.
Experts Discuss Key Topics in Treatment for Newly Diagnosed Multiple Myeloma
Q: Whether or not to transplant, to transplant or not, that is the question. Jesus, what say ye?
Berdeja considers transplantation beneficial for achieving deeper responses and longer remission, but says the decision increasingly depends on patient preferences and risk. Chari adds that evidence does not yet establish transplant as superior for some standard-risk patients, and longer follow-up is needed.
Experts Discuss Key Topics in Treatment for Newly Diagnosed Multiple Myeloma
Q: What are you doing these days for initial therapy for transplant-eligible patients?
Berdeja says quadruplet therapy is now appropriate for most patients, while treatment intensity should be adjusted for frailty, toxicity, and risk. The doctors discuss the roles of CD38 therapy, lenalidomide, dexamethasone, and a proteasome inhibitor.
Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape
Q: How do IDXD and other B7H3 ADCs perform in terms of efficacy and safety?
IDXD and similar ADCs show high response rates in ES-SCLC with manageable toxicities dominated by GI symptoms and some ILD risk; intracranial activity appears parallel to systemic activity, and while adverse events require careful monitoring, the potential survival benefit supports continued development and trial enrollment.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About This Podcast

What is This Podcast about and what kind of topics does it cover?

This program focuses on practical clinical insights across oncology, highlighting real-world treatment challenges, trial results, and care delivery. Episodes frequently explore disparities in access to cutting-edge therapies, evolving targeted and immunotherapy options (including CELMoDs, BCMA-directed therapies, bispecifics, and ADCs), and the practicalities of sequencing, toxicity management, and coordinating multidisciplinary care. Notable strengths include deep dives from leading clinicians and pharmacists, cross-border perspectives on practice patterns, and actionable takeaways for implementing new data in diverse clinical settings. The show often features expert guests from major cancer centers and European institutions, with an empha... more

Where can I find podcast stats for this podcast?

Rephonic provides a wide range of podcast stats for this podcast. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to this podcast and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does this podcast get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for this podcast, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for this podcast?

Rephonic provides comprehensive predictive audience data for this podcast, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does this podcast have?

To see how many followers or subscribers this podcast has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to this podcast?

These podcasts share a similar audience with this podcast:

1. Two Onc Docs
2. Plenary Session
3. NEJM This Week
4. JAMA Editors' Summary
5. JAMA Clinical Reviews

How many episodes of this podcast are there?

this podcast launched 6 years ago and published 274 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact this podcast?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for this podcast?

Rephonic pulls ratings and reviews for this podcast from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for this podcast?

Rephonic provides full transcripts for episodes of this podcast. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on this podcast?

Recent guests on this podcast include:

1. Michael Sprintz
2. Mitchell Engel
3. Amanda Zimmerman
4. Kathy Cates
5. Jesus G. Berdeja
6. Ajai Chari
7. Neeraj Agarwal
8. Emmanuel Antonarakis

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days